Media Release

November 4, 2012 at 4:46 am Leave a comment

Life Sciences Industry Fuels Intangible Assets for Canada’s Economy
Policy Paper Explores Social and Economic Impact of Genomics Research

OTTAWA – October 17, 2012 – The value of genomics research extends beyond commercial success into an overlooked realm of intangible capital that is critical to Canada’s economic and social development, says a new policy paper published by Genome Canada.

Entitled Moving Beyond Commercialization, the paper was written by leading Canadian experts in intellectual property, technology transfer and public policy who examined the strengths related to innovation within the life sciences industry.

Success is frequently defined by growth, sales, and profit. But emerging life science companies are considered high-risk because of the long lead time – up to 10 years or more – to develop a product and show a profit after expensive multi-year investments.

The analysis concluded that commercial success alone is inadequate to measure intangible assets such as scientific knowledge, entrepreneurial experience and industry collaboration that are necessary ingredients to economic and social growth. The authors recommended that other methods be used to assess prosperity and social benefits.

“Policymakers need a thorough understanding of what kind of framework is important to help understand the value of research investment,” said Yann Joly, a Quebec lawyer, researcher and assistant professor of medicine at McGill University. “This is as critical to Canada’s economic well-being as it is to helping formulate new research and innovation policies.”

The document, written by Joly along with Edward S. Dove both of McGill University and Angus Livingstone of the University of British Columbia, is the latest in a series of briefs on genomics policy and society published by Genome Canada.

These papers explore public issues and provide informed debate on topics of social importance and national interest ranging from discrimination to privacy to intellectual property. Researchers will next examine future regulatory options for the genome sciences.

This and other issues will be open for discussion at the Canadian Science Policy Conference, held in Calgary, Nov. 5-7, 2012. See for further information.

The policy paper can be viewed on the Genome Canada web site at

Genome Canada is a catalyst for developing and applying genome science that creates economic wealth and social benefit for Canadians. We work in partnership to invest in and manage large-scale research and translate discoveries into commercial opportunities, new technologies, applications and solutions. We build bridges between government, academia and industry to forge a genomics-based public-private innovation focused on key life science sectors. For more information, visit

– 30 –

For further information, please contact:

Marlene Orton
Director, Media and Communications
Genome Canada
Phone: 613-751-4460 x219
Cell: 613-295-1476

Entry filed under: Biotechnology News, Of Interest. Tags: .

Media Release TGX Stain-Free™ Precast Gels Facilitate LDL Research on Potential New Drug Targets

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Bio-Rad Canada has sponsored the development of this site to advance the productivity of the Canadian Biotechnology sector and the fine people who work in it across the country.  We invite readers to contribute content: posters, tools, research and presentations, articles white papers, multimedia, music downloads and entertainment, conference announcements, videos. Please contact for more information.

Bookmark and Share

Site developed by What If What Next(TM)

Follow us on Twitter

%d bloggers like this: